Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ChiCTR2600120535 Butaselen Cryptogenic Organizing Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120535 clinical trial report covering Butaselen, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07470840 Anlotinib Dihydrochloride Metastatic Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07470840 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120503 Bevacizumab Platinum-Resistant Primary Peritoneal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120503 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07474636 HS-10542 Glomerular disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07474636 clinical trial report covering HS-10542, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07472478 Garsorasib KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07472478 clinical trial report covering Garsorasib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07474324 Disitamab Vedotin HER2-positive gastric cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07474324 clinical trial report covering Disitamab Vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120479 Iparomlimab/Tuvonralimab Unresectable Biliary Tract Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120479 clinical trial report covering Iparomlimab/Tuvonralimab, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07474792 ORKA-002 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07474792 clinical trial report covering ORKA-002, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07474064 Toripalimab Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07474064 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260871 JX2201 Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
CTR20260871 clinical trial report covering JX2201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07474727 Cetuximab Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07474727 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475715 Sublingual Film for Dermatophagoides pteronyssinus(Wolwo Bio-Pharmaceutical) allergic rhinitis due to dust mite Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07475715 clinical trial report covering Sublingual Film for Dermatophagoides pteronyssinus(Wolwo Bio-Pharmaceutical), Phase 2, endpoints, sponsor, geogr